Brind.
From Alvotech Submits Biosimilar Application for Retinal Disease Treatment to EMA

How could Alvotech's regulatory application to the EMA affect the European Commission?

Likely What happens if… A possibility worth considering, not a forecast.

European Commission must review new high-dose biosimilar application Alvotech submitted a regulatory application to the European Medicines Agency (EMA) for AVT29, a proposed biosimilar to Eylea 8 mg. The EMA reviews this application and provides scientific opinions and recommendations. The European Commission is responsible for reviewing these EMA recommendations and subsequently issuing the final market authorization decision for the product in Europe. This submission places the Commission in the formal process of evaluating the high-dose aflibercept biosimilar.

Reported by 1 independent outlet Written Wednesday
Effect
Mixed
How direct
Stated in the reporting
When
Within weeks
The story
No new developments lately

How it reaches European Commission

Reported by news outlets

Tap any step to see the evidence behind it.

The facts so far

As reported. Each one links to where it comes from.

  • Alvotech submitted AVT29 to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli®.manilatimes.net
  • AVT29 is a proposed biosimilar to Eylea® 8 mg (aflibercept 114.3 mg/mL).manilatimes.net
  • The 8mg formulation allows treatment intervals of 16 weeks for certain patients, compared with the standard eight-week maintenance interval.manilatimes.net
  • Mynzepli® received European Commission approval in August 2025 as a biosimilar to Eylea® 2 mg.manilatimes.net

Why it matters

The approval of high-dose biosimilars like AVT29 is critical for improving patient access and reducing treatment costs across Europe. If approved, the high-dose formulation could potentially reduce the frequency of maintenance injections for patients with retinal diseases, thereby lowering the overall treatment burden.

This submission adds to the growing pipeline of biosimilars targeting established drugs like Eylea. The European Commission's role is central to the EU's pharmaceutical market, as its final decision determines the availability and pricing of these high-quality biologic medicines across the bloc.

What we don't know yet

  • What specific scientific opinions will the EMA provide regarding AVT29's biosimilarity?
  • What is the expected timeline for the European Commission to review the EMA's recommendation?

What would change this answer

The EMA issues a positive scientific opinion on AVT29The European Commission's review process will likely accelerate, increasing the certainty of market authorization.
The EMA requests further clinical data from AlvotechThe Commission's review timeline will be extended, delaying the final decision on the high-dose biosimilar.

— Other considerations

Beyond this explainer

Questions worth asking

Ideas the web ties closely to this story that the explainer doesn't mention. These are prompts for your own research: Brind hasn't answered them.

  • About Committee for Medicinal Products for Human Use

    Since the EMA provides scientific opinions, what specific criteria does the CHMP use to evaluate the biosimilarity of AVT29 compared to Eylea?

  • About European Public Assessment Report

    What key data points are included in the European Public Assessment Report that the European Commission would rely on when making its final decision?

Explore connected ideas

Each opens in Related concepts: what the web connects to it, with Brind's news on it.

The ideas come from how millions of web pages place them near each other. The questions are Brind's AI reasoning, written only from this explainer and Brind's own reporting.

Who else could feel it

Other possible ripples from the same event.

Reporting

Keep going

The full eventAlvotech Submits Biosimilar Application for Retinal Disease Treatment to EMA Everything aboutEuropean Commission

Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.